Published in Br J Haematol on July 01, 1999
Drug delivery systems for intraperitoneal therapy. Pharm Res (2010) 1.06
Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid. Int J Pharm (2010) 0.85
Population pharmacokinetics of liposomal daunorubicin in children. Br J Clin Pharmacol (2003) 0.81
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia (2006) 5.64
Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood (1984) 3.65
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst (1998) 2.96
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol (1998) 2.55
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum (2012) 1.96
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab (2007) 1.93
Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia (2009) 1.84
Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood (1998) 1.71
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. Ann Oncol (2009) 1.62
Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood (1996) 1.59
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia (2010) 1.54
Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol (1999) 1.51
Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol (1995) 1.49
Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions. Thyroid (2003) 1.46
Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Br J Haematol (2000) 1.46
Hepatitis C virus infection (and additional neoplasms) among marginal zone lymphomas. Br J Haematol (1997) 1.45
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia (2012) 1.44
Antiproteinuric effect of Losartan in patients with chronic renal diseases. Nephrol Dial Transplant (1997) 1.41
Heat-induced unfolding of neocarzinostatin, a small all-beta protein investigated by small-angle X-ray scattering. J Mol Biol (2001) 1.41
A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. Haematologica (1999) 1.39
CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia (2001) 1.32
Nonsecretory multiple myeloma. Presenting findings, clinical course and prognosis. Acta Haematol (1985) 1.30
An insertion in the human thyrotropin receptor critical for high affinity hormone binding. Science (1990) 1.21
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol (2009) 1.20
The Kell blood group system: Kell and XK membrane proteins. Semin Hematol (2000) 1.20
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant (2010) 1.19
Bortezomib as an antitumor agent. Curr Pharm Biotechnol (2006) 1.17
Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program (2001) 1.16
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica (2001) 1.16
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol (2006) 1.16
Expression of pendrin and the Pendred syndrome (PDS) gene in human thyroid tissues. J Clin Endocrinol Metab (2000) 1.15
Patient-controlled analgesia in children and adolescents: a randomized, prospective comparison with intramuscular administration of morphine for postoperative analgesia. J Pediatr (1991) 1.15
Thyrotropin-luteinizing hormone/chorionic gonadotropin receptor extracellular domain chimeras as probes for thyrotropin receptor function. Proc Natl Acad Sci U S A (1991) 1.15
Staging and prognosis in chronic myelogenous leukemia. Semin Hematol (1988) 1.15
The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia (2006) 1.15
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol (2008) 1.14
Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab (1997) 1.13
Laparoscopic vs open splenectomy in the management of hematologic diseases. Surg Endosc (1999) 1.13
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer (2012) 1.11
The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia (2013) 1.11
Proteolytic processing of big endothelin-3 by the kell blood group protein. Blood (1999) 1.10
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer (2004) 1.10
Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol (1989) 1.10
Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology (2000) 1.10
Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab (1998) 1.08
Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica (1999) 1.07
Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats. Biomaterials (1993) 1.06
The psychosocial impact of multiple sclerosis: exploring the patient's perspective. Health Psychol (1999) 1.05
Percutaneous ethanol injection efficacy in the treatment of large symptomatic thyroid cystic nodules: ten-year follow-up of a large series. Thyroid (2002) 1.04
Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol (2001) 1.03
Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia (2005) 1.03
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. Bone Marrow Transplant (2004) 1.03
The CD34 hemopoietic progenitor cell associated antigen: biology and clinical applications. Haematologica (1992) 1.02
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia (2013) 1.01
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia (2011) 1.00
Serum LDH concentration in non-Hodgkin's lymphomas. Relationship to histologic type, tumor mass, and presentation features. Acta Haematol (1984) 0.98
Adolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy. A study of 293 patients. Blood (1982) 0.98
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia (2012) 0.98
Graves' disease, thyroid nodules and thyroid cancer. Clin Endocrinol (Oxf) (2001) 0.98
Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. J Endocrinol Invest (2004) 0.98
Notch signaling is involved in expression of thyrocyte differentiation markers and is down-regulated in thyroid tumors. J Clin Endocrinol Metab (2008) 0.97
A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis (2001) 0.97
Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. Leukemia (2009) 0.96
Resistance of natural killer T cell-deficient mice to systemic Shwartzman reaction. J Exp Med (2000) 0.96
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia (2011) 0.96
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol (2000) 0.95
Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Mult Scler (1999) 0.95
Stem cell mobilization and collection in patients with liver cirrhosis. Aliment Pharmacol Ther (2008) 0.95
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. Transpl Infect Dis (2013) 0.95
Splenectomy in hematology. Current practice and new perspectives. Haematologica (1999) 0.94
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. Leukemia (2010) 0.94
Hodgkin's disease occurring in a Warthin's tumor: first case report. Pathol Res Pract (1986) 0.94
Binding domains of stimulatory and inhibitory thyrotropin (TSH) receptor autoantibodies determined with chimeric TSH-lutropin/chorionic gonadotropin receptors. J Clin Invest (1991) 0.94
Photodynamic therapy of ascites tumours within the peritoneal cavity. Br J Cancer (1986) 0.94
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. Pharmacogenomics J (2012) 0.94
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia (2006) 0.93
Investigation of the presence of ghrelin in the central nervous system of the rat and mouse. Neuroscience (2011) 0.93
Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. Bone Marrow Transplant (2007) 0.92
Prognostic variables and clinical staging in multiple myeloma. Blood (1989) 0.92
Effects of water hardness on urinary risk factors for kidney stones in patients with idiopathic nephrolithiasis. Nephron (1999) 0.92
Renal failure in multiple myeloma. A study of the presenting findings, response to treatment and prognosis in 26 patients. Nouv Rev Fr Hematol (1986) 0.91
Castleman's disease: an unusual cause of mediastinal mass and anemia. Clin Ter (2002) 0.90
Second malignancy in patients treated by Hodgkin's disease. Cancer (1980) 0.90